This brand name is authorized in Japan, Turkey, South Africa
The drug SYNVISC contains one active pharmaceutical ingredient (API):
|
1
Hyaluronic acid derivative Hylan G-F 20
UNII 01OUW6MA4L - HYLAN G-F 20
|
|
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| M09AX01 | Hyaluronic acid | M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 3999428G1023 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699809950788, 8699809950795 |
| Country: ZA | Health Products Regulatory Authority | Identifier(s): 31/3.2/0397, 45/3.2/0025 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
